Compare AbbVie Inc (ABBV) vs Shell PLC (SHEL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Shell PLC — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while Shell PLC trades at $82.29 (market cap $220.29B). The key difference: AbbVie Inc is far larger — about 2× Shell PLC's market cap, and Shell PLC pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| ABBV | SHEL | |
|---|---|---|
Market Cap | $449.91B | $220.29B |
Sector | Health | Energy |
52-Week High | $261.07 | $94.15 |
52-Week Low | $184.85 | $70.28 |
Enterprise Value | $513.38B | $272.82B |
Dividend Yield | 2.72% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates solid revenue growth, reaching $61.16B in 2025, though net margins have compressed to 5.79%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $2.65 exceeding the $2.59 forecast. Positive clinical trial results for ELAHERE in ovarian cancer and institutional buying activity support investor confidence.
AbbVie presents a favorable risk-reward profile with 68% analyst buy ratings and a $266.33 consensus price target offering 5.4% upside. Key opportunities include Skyrizi/Rinvoq growth offsetting Humira declines, while risks involve patent expirations in the 2030s and margin pressure. The stock's elevated P/E of 124.83 reflects growth expectations but warrants monitoring of execution against guidance.
Shell (SHEL) trades at $81.99, up 5.09% on the day, with strong analyst support showing 69% buy ratings and a $112.10 consensus price target. The stock shows attractive valuation metrics with P/E of 12.17 and P/S of 0.86, while recent Q1 2026 earnings beat expectations. However, technical indicators signal bearish momentum despite positive news about stronger gas trading performance and improved refining margins ahead of Q2 results.
Shell presents a compelling value opportunity with solid profitability (7.01% net margin) and strong cash flow generation, though faces headwinds from declining revenue trends and geopolitical risks affecting production. The company's strategic focus on LNG growth and portfolio optimization supports long-term prospects, but investors should monitor execution risks and oil price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
